Klinická farmakologie a farmacie – 3/2018

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2019; 33(3): 11–16 /  www.klinickafarmakologie.cz 16 ORIGINÁLNÍ PRÁCE Targeting asthma control in real‑life clinical practice by using ICS/LABA combination latively high proportion of enrolled patients with chronic bronchitis or COPD as comorbid conditi­ ons (29%). However, the two diagnoses were not confirmed by performing bronchial reversibility testing with respect to a real‑life design close to everyday clinical practice and possible additional workload for participating physicians. Generally, the proportion of patients with features of both asthma and chronic bronchitis/COPD is unclear and woud have been influenced by the initial inclusion criteria used for the studies fromwhich the data were drawn. In epidemiological studies, the reported prevalence rates for asthma‑COPD overlap have ranged between 15% and 55%, with variation by gender and age, and the wide range reflects the different criteria that have been used (2). Another cross‑sectional observational stu­ dy using a stepwise approach according to the GINA/GOLD guidelines identified only 9.2% of COPD patients as having asthma‑COPD overlap (21). It is well known that asthma/COPD overlap syndrome is associatedwith amore severe course of the disease, lower related quality of life, and more frequent exacerbations (22). Our study had several limitations. These included the real‑life design and absence of a control group. In addition, a three‑month follow‑up does not provide a sufficient possi­ bility to monitor the maintenance of long‑term asthma control and its impact on the frequency of flare‑ups and other serious events as well. Conclusion In a majority of uncontrolled asthmatic patients, significant improvement of disease control represents an achievable goal thanks to an appropriate pharmacological strategy coupled with interventions aimed at a proper inhaler technique and adherence. Along with treatment of the underlying disease, it is im­ portant to pay close attention to comorbidities and smoking cessation. REFERENCES 1. Hrubiško M, Čižnár, P et al. Asthma bronchiale. Národné smernice pre terapiu. BONUS, Bratislava 2010. 2. Global initiative for asthma: GINA Report, Global Strategy for Asthma Management and Prevention, 2017. Available at: file:///C:/Users/monik/Downloads/wms‑GINA‑main‑pocket‑guide_2018-v1. 0. pdf (Date accessed: 17. 05. 2019). 3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. GOAL Investigators Group: Can guideline‑defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–844. 4. Allegra L, Cremonesi G, Girbino G, et al. (PRospectIve Study on asthMA control) Study Group, Real‑life prospective study on asthma control in Italy: cross‑sectional phase results. Re­ spir Med 2012; 106: 205–214. 5. Demoly P, Paggiaro P, Plaza V, Bolge SC, Kannan H, Sohier B, AdamekL.Prevalenceofasthmacontrolamongadults inFrance, Germany, Italy,SpainandtheUK.EurRespirRev2009;18:105–112. 6. Eucan Aim Executive Summary 2010. http://www.takingai­ matasthma.eu/ (Date accessed: 17. 05. 2019). 7. Braido F. Failure in asthma control: reasons and consequen­ ces. Scientifica 2013; Article ID 549252, 15 p. http://dx.doi. org/10.1155/2013/549252 (Date accessed: 17. 05. 2019). 8. Greening AP, Ind PW, Northfield M, Shaw G. Added salmete­ rol versus higher‑dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Han­ burys Limited UK Study Group. Lancet 1994; 344: 219–224. 9. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inha­ led formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) International study group. N Engl J Med 1997; 337: 1405–1411. 10. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma con­ trol. J Allergy Clin Immunol 2004; 113: 59–65. 11. Pellegrino R, Viegl G, Brusasco V, et al. Interpretative strate­ gies for lung function tests. Eur Respir J 2005; 26(5): 948–968. 12. Bateman ED, Bousquet J, Busse WW, Clark TJ, Gul N, Gibbs M, Pedersen S; GOAL Steering Committee and Investigators: Stability of asthma control with regular treatment: an analysis of the GOAL study. Allergy 2008; 63: 932–938. 13. Murray J, Rosenthal R, Somerville L, et al. Fluticasone pro­ pionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short‑acting β2-agonists. Ann Allergy Asthma Immunol 2004; 93: 351–359. 14. Schmidlt O, Petro W, Hoheisel G, Kanniess F, Oepen P, Langer‑Brauburger B: Real‑life effectiveness of asthma tre­ atment with a xed‑dose uticasone/formoterol pressuris­ ed metered‑dose inhaler eResults from a non‑interventional study. Respiratory Medicine 2017; 131: 166–174. 15. Lundbäck B, Rönmark E, Lindberg A, Jonsson ACH, Larsson LG, James M. Asthma control over 3 years in a real‑life study. Respir Med 2009; 103: 348–355. 16. Braido F, Baiardini I, Bordo A, Menoni S, et al. Coping with asthma: is the physician able to identify patient’s be­ haviour? Respir Med 2012; c106: 1625–1630. 17. Terzano C, Cremonesi G, Girbino G, et al. on behalf of the PRISMA (PRospectIve Study on asthMA control) Stu­ dy Group: 1-year prospective real life monitoring of ast­ hma control and quality of life in Italy. Respir Res 2012; 13: 112–123. 18. Al‑Jahdali H, Ahmed A, Al‑Harbi A, et al. Improper inha­ ler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol 2013; 9: 8–18. 19. Al‑Zahrani JM, Ahmad A, Al‑Harbi A, et al. Factor associa­ ted with poor asthma control in the outpatient clinic setting. Ann Thorac Med 2015; 10: 100–104. 20. Yildiz F and On behalf of the ASIT Study Group: Factors influencing asthma control: results of a real‑life prospective observational asthma inhaler treatment (ASIT) study. J Asthma Allergy 2013; 6: 93–101. 21. Inoue H, Nagase T, Morita S, et al. Prevalence and cha­ racteristics of asthma‑COPD overlap syndrome identified by a stepwise approach. In J COPD 2017; 12: 1803–1810. 22. Hardin M, Silverman EK, Barr RG, et al. COPD Gene In­ vestigators: The clinical features of the overlap between COPD and asthma. Respir 2011; 12: 127–135.